Cargando…

Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine

Neonatal herpes is a dreaded complication of genital herpes infection in pregnancy. We recently compared two vaccine platforms for preventing genital herpes in female mice and guinea pigs and determined that HSV-2 glycoproteins C, D and E expressed using nucleoside-modified mRNA in lipid nanoparticl...

Descripción completa

Detalles Bibliográficos
Autores principales: LaTourette, Philip C., Awasthi, Sita, Desmond, Angela, Pardi, Norbert, Cohen, Gary H., Weissman, Drew, Friedman, Harvey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545304/
https://www.ncbi.nlm.nih.gov/pubmed/33041105
http://dx.doi.org/10.1016/j.vaccine.2020.09.079
_version_ 1783592006548717568
author LaTourette, Philip C.
Awasthi, Sita
Desmond, Angela
Pardi, Norbert
Cohen, Gary H.
Weissman, Drew
Friedman, Harvey M.
author_facet LaTourette, Philip C.
Awasthi, Sita
Desmond, Angela
Pardi, Norbert
Cohen, Gary H.
Weissman, Drew
Friedman, Harvey M.
author_sort LaTourette, Philip C.
collection PubMed
description Neonatal herpes is a dreaded complication of genital herpes infection in pregnancy. We recently compared two vaccine platforms for preventing genital herpes in female mice and guinea pigs and determined that HSV-2 glycoproteins C, D and E expressed using nucleoside-modified mRNA in lipid nanoparticles provided better protection than the same antigens produced as baculovirus proteins and administered with CpG and alum. Here we evaluated mRNA and protein immunization for protection against neonatal herpes. Female mice were immunized prior to mating and newborns were infected intranasally with HSV-2. IgG binding and neutralizing antibody levels in mothers and newborns were comparable using the mRNA or protein vaccines. Both vaccines protected first and second litter newborns against disseminated infection based on virus titers in multiple organs. We conclude that both vaccines are efficacious at preventing neonatal herpes, which leaves the mRNA vaccine as our preferred candidate based on better protection against genital herpes.
format Online
Article
Text
id pubmed-7545304
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75453042020-10-09 Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine LaTourette, Philip C. Awasthi, Sita Desmond, Angela Pardi, Norbert Cohen, Gary H. Weissman, Drew Friedman, Harvey M. Vaccine Short Communication Neonatal herpes is a dreaded complication of genital herpes infection in pregnancy. We recently compared two vaccine platforms for preventing genital herpes in female mice and guinea pigs and determined that HSV-2 glycoproteins C, D and E expressed using nucleoside-modified mRNA in lipid nanoparticles provided better protection than the same antigens produced as baculovirus proteins and administered with CpG and alum. Here we evaluated mRNA and protein immunization for protection against neonatal herpes. Female mice were immunized prior to mating and newborns were infected intranasally with HSV-2. IgG binding and neutralizing antibody levels in mothers and newborns were comparable using the mRNA or protein vaccines. Both vaccines protected first and second litter newborns against disseminated infection based on virus titers in multiple organs. We conclude that both vaccines are efficacious at preventing neonatal herpes, which leaves the mRNA vaccine as our preferred candidate based on better protection against genital herpes. Elsevier Ltd. 2020-11-03 2020-10-09 /pmc/articles/PMC7545304/ /pubmed/33041105 http://dx.doi.org/10.1016/j.vaccine.2020.09.079 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
LaTourette, Philip C.
Awasthi, Sita
Desmond, Angela
Pardi, Norbert
Cohen, Gary H.
Weissman, Drew
Friedman, Harvey M.
Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
title Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
title_full Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
title_fullStr Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
title_full_unstemmed Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
title_short Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
title_sort protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mrna in lipid nanoparticle vaccine
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545304/
https://www.ncbi.nlm.nih.gov/pubmed/33041105
http://dx.doi.org/10.1016/j.vaccine.2020.09.079
work_keys_str_mv AT latourettephilipc protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine
AT awasthisita protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine
AT desmondangela protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine
AT pardinorbert protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine
AT cohengaryh protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine
AT weissmandrew protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine
AT friedmanharveym protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine